Emergency Use Authorisation of Vaccines | UPSC

Emergency Use Authorisation of Vaccines | UPSC


What is the emergency use authorisation drugmakers are seeking for Covid-19 vaccine?

      WHY IN NEWS:

  • Vaccines, like medicines, require the approval of a regulatory authority before these can be administered.
  • In India, the top regulatory authority is the Central Drugs Standard Control Organisation, or CDSCO.
SYLLABUS COVERED: GS 3:Health:Diseases


A few days earlier, Pfizer applied for emergency use authorisation for the vaccine it has developed in collaboration with BioNTech.

  • The fastest approval for any vaccine until now — the mumps vaccine in the 1960s — took about four-and-a-half years after it was developed.
  • On Monday, US drugmaker Moderna said it was applying for emergency use authorisation for its Covid-19 vaccine.
  • In India, Serum Institute of India trialling ; AstraZeneca-Oxford vaccine will seek emergency use authorisation within the next two weeks.


  • Vaccines and medicines, and even diagnostic tests and medical devices, require the approval of a regulatory authority before they can be administered.

In India, the regulatory authority is the Central Drugs Standard Control Organisation (CDSCO).

  • For vaccines and medicines, approval is granted after an assessment of their safety and effectiveness, based on data from trials.
  • In fact, approval from the regulator is required at every stage of these trials.
  • This is a long process, designed to ensure that a medicine or vaccine is absolutely safe and effective.
  • In emergency situations, like the current one, regulatory authorities around the world have developed mechanisms to grant interim approvals.
  • Final approval is granted only after completion of the trials and analysis of full data;
  • Emergency use authorisation (EUA) allows the medicine or the vaccine to be used on the public.


  • In the US, the Food and Drug Administration (FDA) grants an EUA .
  • This is only after it has been determined that the “known and potential benefits outweigh the known and potential risks of the vaccine” (or medicine).
  • This means that an EUA application can be considered only after sufficient efficacy data from phase 3 trials had been generated.

An EUA cannot be granted solely on the basis of data from phase 1 or phase 2 trials, although these too need to show the product is safe. 

  • For Covid-19 vaccines, the FDA has specified that it would consider an application for EUA only if phase 3 data showed it was at least 50% effective in preventing the disease.
  • This data needed to be generated from “well over” 3,000 trial participants, “representing a high proportion of participants” enrolled.
  • These participants needed to be followed up for any serious adverse effects for at least one month after all dosages had been given.

Emergency Use Authorisation of Vaccines | UPSC


  • India’s drug regulations do not have provisions for an EUA, and the process for receiving one is not clearly defined or consistent.

Despite this, CDSCO has been granting emergency or restricted emergency approvals to Covid-19 drugs during this pandemic.

Remdesivir and favipiravir in June, and itolizumab in July.

  • “The US FDA regulations are clear about the conditions and process for receiving an EUA.
  • Drugs that have received restricted emergency approvals in India, like itolizumab, were not subsequently included in the country’s Covid-19 Clinical Management Guidelines.
  • So, what was the basis for the ‘approval’ and why is that not good enough for it to be included in the treatment protocol.


  • Any company seeking to launch a vaccine approved elsewhere would have to conduct local trials to prove it is safe and effective on the Indian population.
  • Serum Institute of India is conducting trials of its version, Covishield, on around 1,600 participants in India.

Bharat Biotech is currently conducting phase 3 trials of its vaccine, Covaxin, and has said it will not be approaching CDSCO for an EUA.

  • Dr Reddy’s Laboratories (DRL) is hoping to start phase 2/3 trials of the Russian Sputnik V vaccine.
  • AstraZeneca and Oxford University have published interim findings of their vaccine’s efficacy.
  • It is possible that SII will push for an EUA to market the vaccine in India sooner, on the basis of the results of its small-scale trials in India.


  • EUA is a relatively recent phenomenon.
  • The FDA granted its first EUA for the civilian population in 2009.
  • The first EUA allowed the use of Tamiflu drug for infants and young children for the treatment of H1N1 infection.

EUAs have been granted for several medicines, diagnostics, and equipment like ventilators or even PPEs, but never for a vaccine.

  • An EUA can be granted only in a declared public health emergency; previous EUAs came during the spread of the Ebola virus, Zika virus and MERS coronavirus.
  • Remdesivir or faviparir, which received EUA for treatment of Covid-19, including in India, are existing drugs approved for other ailments.

      IASbhai WINDUP: 


  • According to the US FDA, the public has to be informed that a product has only been granted an EUA and not full approval.
  • In the case of a Covid-19 vaccine, for example, people have to be informed about the known and potential benefits and risks

The “extent to which such benefits or risks are unknown”, and that they have a right to refuse the vaccine.

  • There has been an ongoing debate over whether people have the option of refusing to take the vaccine.
  • Incidentally, no country has made vaccination compulsory for its people.
  • Initially, all vaccines are likely to be deployed on emergency use authorisations only.
  • Final approval from respective authorities may take several months, or years.
     SOURCES:   PIB | Emergency Use Authorisation of Vaccines | UPSC



If you liked this article, then please subscribe to our YouTube Channel for Daily Current Affairs , Editorial Analysis & Answer writing video tutorials. You can also find us on Twitter and Facebook.

You May Also Like